Literature DB >> 24179151

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Sietse M Aukema1, Markus Kreuz, Christian W Kohler, Maciej Rosolowski, Dirk Hasenclever, Michael Hummel, Ralf Küppers, Dido Lenze, German Ott, Christiane Pott, Julia Richter, Andreas Rosenwald, Monika Szczepanowski, Carsten Schwaenen, Harald Stein, Heiko Trautmann, Swen Wessendorf, Lorenz Trümper, Markus Loeffler, Rainer Spang, Philip M Kluin, Wolfram Klapper, Reiner Siebert.   

Abstract

Chromosomal translocations affecting the MYC oncogene are the biological hallmark of Burkitt lymphomas but also occur in a subset of other mature B-cell lymphomas. If accompanied by a chromosomal break targeting the BCL2 and/or BCL6 oncogene these MYC translocation-positive (MYC(+)) lymphomas are called double-hit lymphomas, otherwise the term single-hit lymphomas is applied. In order to characterize the biological features of these MYC(+) lymphomas other than Burkitt lymphoma we explored, after exclusion of molecular Burkitt lymphoma as defined by gene expression profiling, the molecular, pathological and clinical aspects of 80 MYC-translocation-positive lymphomas (31 single-hit, 46 double-hit and 3 MYC(+)-lymphomas with unknown BCL6 status). Comparison of single-hit and double-hit lymphomas revealed no difference in MYC partner (IG/non-IG), genomic complexity, MYC expression or gene expression profile. Double-hit lymphomas more frequently showed a germinal center B-cell-like gene expression profile and had higher IGH and MYC mutation frequencies. Gene expression profiling revealed 130 differentially expressed genes between BCL6(+)/MYC(+) and BCL2(+)/MYC(+) double-hit lymphomas. BCL2(+)/MYC(+) double-hit lymphomas more frequently showed a germinal center B-like gene expression profile. Analysis of all lymphomas according to MYC partner (IG/non-IG) revealed no substantial differences. In this series of lymphomas, in which immunochemotherapy was administered in only a minority of cases, single-hit and double-hit lymphomas had a similar poor outcome in contrast to the outcome of molecular Burkitt lymphoma and lymphomas without the MYC break. Our data suggest that, after excluding molecular Burkitt lymphoma and pediatric cases, MYC(+) lymphomas are biologically quite homogeneous with single-hit and double-hit lymphomas as well as IG-MYC and non-IG-MYC(+) lymphomas sharing various molecular characteristics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24179151      PMCID: PMC3971083          DOI: 10.3324/haematol.2013.091827

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  53 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

2.  Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group.

Authors:  B Schlegelberger; T Zwingers; L Harder; H Nowotny; R Siebert; M Vesely; H Bartels; R Sonnen; G Hopfinger; A Nader; G Ott; K Müller-Hermelink; A Feller; R Heinz
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

3.  twilight; a Bioconductor package for estimating the local false discovery rate.

Authors:  Stefanie Scheid; Rainer Spang
Journal:  Bioinformatics       Date:  2005-04-07       Impact factor: 6.937

4.  Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.

Authors:  Eugenia Haralambieva; Evert-Jan Boerma; Gustaaf W van Imhoff; Stefano Rosati; Ed Schuuring; Hans Konrad Müller-Hermelink; Philip M Kluin; German Ott
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

5.  Molecular diagnosis of Burkitt's lymphoma.

Authors:  Sandeep S Dave; Kai Fu; George W Wright; Lloyd T Lam; Philip Kluin; Evert-Jan Boerma; Timothy C Greiner; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Hans-Konrad Müller-Hermelink; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Thomas M Grogan; Elias Campo; Elaine S Jaffe; Bhavana J Dave; Warren Sanger; Martin Bast; Julie M Vose; James O Armitage; Joseph M Connors; Erlend B Smeland; Stein Kvaloy; Harald Holte; Richard I Fisher; Thomas P Miller; Emilio Montserrat; Wyndham H Wilson; Manisha Bahl; Hong Zhao; Liming Yang; John Powell; Richard Simon; Wing C Chan; Louis M Staudt
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

6.  Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?

Authors:  Anneke G Bosga-Bouwer; Anke van den Berg; Eugenia Haralambieva; Debora de Jong; Ronald Boonstra; Philip Kluin; Eva van den Berg; Sibrand Poppema
Journal:  Hum Pathol       Date:  2006-05       Impact factor: 3.466

7.  Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas.

Authors:  K Bhatia; G Spangler; G Gaidano; N Hamdy; R Dalla-Favera; I Magrath
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

8.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Authors:  Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

9.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas.

Authors:  W Y Au; D E Horsman; H Ohno; R J Klasa; R D Gascoyne
Journal:  Leuk Lymphoma       Date:  2002-04
View more
  47 in total

1.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Parth A Desai; Pei Lin; Jason R Westin; Huda M Hawsawi; Peng Wei; Guilin Tang; Adam C Seegmiller; Nishitha M Reddy; C Cameron Yin; Wei Wang; Jie Xu; Roberto N Miranda; Zhuang Zuo; Shaoying Li
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Authors:  Christopher D Carey; Daniel Gusenleitner; Bjoern Chapuy; Alexandra E Kovach; Michael J Kluk; Heather H Sun; Rachel E Crossland; Chris M Bacon; Vikki Rand; Paola Dal Cin; Long P Le; Donna Neuberg; Aliyah R Sohani; Margaret A Shipp; Stefano Monti; Scott J Rodig
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

Review 3.  Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Authors:  Siba El Hussein; Kenna R M Shaw; Francisco Vega
Journal:  Mod Pathol       Date:  2020-07-03       Impact factor: 7.842

4.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Authors:  Rossella Marullo; Sarah C Rutherford; John P Leonard; Leandro Cerchietti
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

5.  Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.

Authors:  Alexandra Valera; Samantha Epistolio; Lluis Colomo; Alice Riva; Olga Balagué; Ivan Dlouhy; Alexandar Tzankov; Marco Bühler; Eugenia Haralambieva; Elias Campo; Davide Soldini; Luca Mazzucchelli; Vittoria Martin
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

Review 6.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Authors:  Grzegorz S Nowakowski; Kristie A Blum; Brad S Kahl; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; David G Maloney; Laurie H Sehn; Michael E Williams; Wyndham H Wilson; John P Leonard; Sonali M Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-16       Impact factor: 13.506

7.  Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Authors:  Sietse M Aukema; Giorgio A Croci; Reiner Siebert; Wolfram Klapper; Susanne Bens; Kathrin Oehl-Huber; Rabea Wagener; German Ott; Andreas Rosenwald; Philip M Kluin; Eva van den Berg; Anneke G Bosga-Bouwer; Mels Hoogendoorn; Eva Hoster; Iris Bittmann; Inga Nagel; Eva M Murga Penas; Markus Kreuz; Julia Bausinger; Wilfried Belder; Ilske Oschlies; Martin J S Dyer; Sandrine Jayne
Journal:  Virchows Arch       Date:  2021-02-02       Impact factor: 4.064

Review 8.  Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Authors:  Andrew Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

9.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.

Authors:  Rabea Wagener; Cristina López; Kortine Kleinheinz; Julia Bausinger; Sietse M Aukema; Inga Nagel; Umut H Toprak; Julian Seufert; Janine Altmüller; Holger Thiele; Christof Schneider; Julia Kolarova; Jeongbin Park; Daniel Hübschmann; Eva M Murga Penas; Hans G Drexler; Andishe Attarbaschi; Randi Hovland; Eigil Kjeldsen; Michael Kneba; Udo Kontny; Laurence de Leval; Peter Nürnberg; Ilske Oschlies; David Oscier; Brigitte Schlegelberger; Stephan Stilgenbauer; Wilhelm Wössmann; Matthias Schlesner; Birgit Burkhardt; Wolfram Klapper; Elaine S Jaffe; Ralf Küppers; Reiner Siebert
Journal:  Blood       Date:  2018-10-03       Impact factor: 22.113

10.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Adam M Petrich; Benjamin A Chu; Amir Behdad; Shaoying Li; L Jeffrey Medeiros; Ryan D Cassaday; Nishitha M Reddy; Martin A Bast; Julie M Vose; Kimberly R Kruczek; Scott E Smith; Priyank Patel; Francisco Hernandez-Ilizaliturri; Reem Karmali; Saurabh Rajguru; David T Yang; Joseph J Maly; Kristie A Blum; Weiqiang Zhao; Charles Vanslambrouck; Chadi Nabhan
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.